UK Supreme Court invalidates Eli Lilly patent relating to Cialis

The UK Supreme Court has ruled in favour of Actavis (which has been acquired by Teva) and Mylan in a patent dispute against Eli Lilly, after an earlier court found that one of Eli Lilly’s patents was invalid for lacking an inventive step.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Eli Lilly avoids sanctions in Teva migraine treatment dispute

13 January 2022 Teva Pharmaceuticals has failed to persuade a federal judge in Massachusetts that Eli Lilly should be penalised over its discovery search related to a patent dispute concerning a migraine treatment.

Big Pharma

Eli Lilly enters $35m immunology R&D deal

25 April 2019 Eli Lilly has entered into a $35m global licensing and research agreement with biotech company Avidity Biosciences.

Big Pharma

Eli Lilly defeat shows one size does not fit all in obviousness test: lawyers

28 March 2019 The UK Supreme Court’s decision in Actavis v Eli Lilly confirms that a multi-factorial judgement should be used to determine whether an invention is obvious or not, lawyers have told WIPR.